Intravenous Amiodarone Infusion Protocol and Clinical Management

1. Infusion Regimen for Life‑Threatening Ventricular Arrhythmias

• Administer a 150 mg IV bolus over 10 minutes, then infuse 1 mg/min for 6 hours followed by 0.5 mg/min for the next 18 hours, delivering ≈1,050 mg total in the first 24 hours. 1

2. Cardiac‑Arrest Dosing Modification

• For pulseless VT/VF unresponsive to defibrillation and epinephrine, give a 300 mg IV/IO bolus; if the rhythm persists, give an additional 150 mg bolus. 1

3. Safety Monitoring

Cardiovascular Adverse Events

• Hypotension occurs in 16–26 % of patients receiving IV amiodarone; manage by slowing the infusion, adding vasopressors, inotropes, or volume expansion as needed. 1
• Bradycardia and new AV block occur in ≈4.9 % of patients; consider slowing or stopping the infusion if heart rate falls below 50 bpm or block develops. 1
• QT prolongation is common but rarely leads to torsades de pointes; obtain daily ECGs and intervene if QT > 500 ms. 1

Continuous Monitoring

• Maintain continuous cardiac telemetry for at least 24 hours after starting IV amiodarone. 2
• Perform a 12‑lead ECG daily to assess QT interval and detect heart block. 2

4. Drug‑Interaction Adjustments

• Reduce digoxin dose by 50 % immediately when IV amiodarone is initiated (amiodarone roughly doubles digoxin levels). 2
• Reduce warfarin dose by 30–50 % and re‑check INR 3–5 days after starting IV amiodarone (amiodarone markedly increases anticoagulation). 2

5. Atrial Fibrillation (AF) Rate‑Control Recommendations

• In patients with AF plus heart failure or an accessory pathway, amiodarone is a Class IIa recommendation for rate control. 3
• Rate‑control effect typically appears after several days of therapy, not immediately. 3
• Amiodarone is not first‑line for rate control in hemodynamically stable AF without heart failure; β‑blockers, diltiazem, or verapamil (Class I) achieve rate control within 2–7 minutes. 3

6. Transition from Intravenous to Oral Therapy

• Begin oral amiodarone while the IV infusion continues at 0.5 mg/min; discontinue the IV infusion after 24 hours of oral dosing to ensure adequate tissue saturation. 2
• After completing the 10 g cumulative oral load, reduce maintenance to 200–400 mg daily (some patients require 100–200 mg daily). 5

7. Long‑Term Efficacy Outcome

• At 1 year after cardioversion, 62 % of patients maintained sinus rhythm with oral amiodarone versus 23 % with Class I antiarrhythmic agents. 2

8. Common Pitfalls and Contraindicated Practices

• Do not use IV calcium‑channel blockers or digoxin in AF with a pre‑excitation syndrome; they may paradoxically accelerate ventricular response. 3
• Do not use IV calcium‑channel blockers in decompensated heart failure with AF; they can worsen hemodynamics. 3
• Expect that the full anti‑arrhythmic effect of amiodarone takes days to weeks despite therapeutic serum levels. 5
• Always check and correct serum potassium and magnesium before and during amiodarone therapy, as deficiencies increase pro‑arrhythmic risk. 2